

140
PATIENTS
RECRUITED


Issue no.9 November 2023

NEWS

Last month was a busy and brilliant month for CHIP-BCIS3. We reached (and passed) the **50%** recruitment mark! Thank you to all sites for getting us to this special milestone.

Since our last newsletter in August we have opened two new sites bringing us to a total of 20 open sites. A very warm welcome to Musgrove Park Hospital, Taunton and Golden Jubilee National Hospital, Glasgow.

In October, we randomised a total of **15 participants.** Incredible work to all the teams below!



We also held our final Investigators' Meeting on Friday 13th October. See the second page for a brief overview of the day. Thank you to everyone who contributed to such a valuable and positive afternoon.



Well done to **Essex CTC, Basildon** who randomised the **125th** participant! A hamper is on its way to you!





Amazing work to **QEH Birmingham** for randomising **4** participants in October!

A record number of randomisations in a calendar month!





Musgrove Park Hospital, Taunton and Royal Victoria Hospital, Belfast randomised their 1st participants in October, welcome to the leaderboard!





CHIP-BCIS3 INVESTIGATORS' MEETING OVERVIEW



Friday 13th October 2023 King's College London, Strand

Prof. Divaka Perera, Chief Investigator, welcomed everyone and introduced the meeting.

Dr. Matt Ryan gave a trial update. He emphasised the importance of recruiting the right patients into the trial. If the trial can recruit 12 participants per month, we will finish recruitment in August 2024. This translates to an achievable goal of 1 patient every 2 months from each open site. The trial protocol paper has also been submitted to Circulation: Cardiovascular Interventions.

Dr. Saad Ezad gave a talk on CHIP-BCIS3 sub-studies and presented the

coronary physiology sub-study hypothesis.

Prof. Divaka Perera closed the meeting by thanking everyone who attended, and contributed to a positive and brilliant meeting. He emphasised each patient is an incredibly complex case, who are very unwell and we should be incredibly proud of our achievements so far.

We are now 123 patients away from answering the research question on whether we can improve patient outcomes even more with one strategy compared to the other. Highlights of the meeting follow below.





KEY NOTE LECTURE

Prof. Holger Thiele Heart Center Leipzip, Germany

Keynote speaker Prof. Holger gave Thiele compelling a presentation, showing that existing dogma can be challenged such as in the CULPRIT-SHOCK trial.

He focused on the challenges in setting up past SHOCK trials, particularly the issues relating to the use of devices outside of trial and the exclusion of patients, how informed consent differs per country and also the importance of consistent pragmatic definitions for device trials.

LIVE CASE

Essex CTC, Basildon

It was very exciting to see a live case presented by the team at Essex Cardiothoracic Centre, Basildon.

The patient was a 82 year old female who had been randomised to no IVunloading.

The group discussed the importance of putting all suitable patients that meet the eligibility criteria into CHIP-BCIS3 (unless thev decline) to reduce bias.





IMPELLA WEANING AND POST CATH LAB **MANAGEMENT**

Dr. Vas Panoulas Harefield Hospital, London

Dr. Vas Panoulas presented case studies whilst addressing the issues and complications around Impella management and advice on how to avoid bleeding. He highlighted that when using Impella, the patient needs to gain the maximum benefit from it by deploying and using it as safely and as effectively as possible. Vas also presented the Harefield Impella Emergency Algorithm, which illustrates how to manage a patient who has a cardiac arrest with Impella.

LESSONS FROM THE MIDLANDS Prof. James Cotton, New Cross Hospital, Wolverhampton

Prof. Cotton started with a presentation of their first case and highlighted the need for investigators to pause and assess LV function for all eligible patients, rather than going directly to the cath lab for revascularisation.



HIGH-RISK PCI THE WELSH PERSPECTIVE Prof. Alex Chase, Morriston Hospital, Swansea

Prof. Chase described the challenging process to approve the CHIP-BCIS3 trial as a site newly establishing an Impella program. He expressed enthusiasm to participate in the trial to expand the evidence around use of the Impella device and presented a brief overview of the three cases performed so far.

OVERCOMING CHALLENGES AND MANAGING STRESS Dr. Julian Strange, Bristol Heart Institute

Dr. Strange presented key tips and tools in reducing and managing stress in the workplace including patient and team communication, equipment and preparedness, patient comfort, minimising noise and distractions in the cath lab, mental preparedness, following protocols and debriefing the team after each case.



REMINDERS

SCREENING AND PLVAD (IMPELLA) USE LOGS

Golden Jubilee National Hospital, Glasgow

Musgrove Park Hospital, Taunton

Please send us your detailed monthly screening log and pLVAD (Impella) use log.

They provide us with key information on how many eligible patients are screened, consented, and insights into why participants are excluded from the trial.



SUBSTANTIAL AMENDMENT 2


Substantial amendment 2 should now be implemented at all sites, unless your R&D has asked for more time to review. Please send us your localised versions to check before use.

INVOICING



We have now been in touch with sites on the patient payments for invoicing.

Apologies for the delay in setting up this process and we thank you for your patience.



CONTACT US



If you have any questions please don't hesitate to contact the CTU team - Matt Kwok, Megan Knight, Laura Van Dyck and Richard Evans. Email: CHIP-BCIS3@LSHTM.ac.uk

Tel: +44 (0)20 7927 2723 **Twitter**: @CHIP_BCIS3







